Srikripa Devarakonda
Stock Analyst at Truist Securities
(1.88)
# 2,954
Out of 4,827 analysts
64
Total ratings
29.51%
Success rate
-6.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $6.81 | +61.53% | 1 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $975 → $940 | $547.67 | +71.64% | 7 | Apr 30, 2025 | |
| BIIB Biogen | Maintains: Buy | $210 → $199 | $118.39 | +68.09% | 4 | Apr 29, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $14.02 | +78.32% | 5 | Apr 9, 2025 | |
| INCY Incyte | Maintains: Hold | $74 → $72 | $59.73 | +20.54% | 9 | Mar 18, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $43.92 | +73.04% | 2 | Mar 11, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $751.45 | +38.13% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $185.58 | +16.93% | 3 | Feb 3, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $22.97 | +39.31% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $14.70 | +240.14% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $45 | $30.99 | +45.21% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $30.77 | +72.25% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.75 | +2,985.71% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $6.94 | +116.14% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $9.64 | +273.44% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $32.48 | +115.52% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $60 | $0.70 | +8,471.43% | 2 | Aug 11, 2023 |
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $6.81
Upside: +61.53%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Buy
Price Target: $975 → $940
Current: $547.67
Upside: +71.64%
Biogen
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $118.39
Upside: +68.09%
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $14.02
Upside: +78.32%
Incyte
Mar 18, 2025
Maintains: Hold
Price Target: $74 → $72
Current: $59.73
Upside: +20.54%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $43.92
Upside: +73.04%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $751.45
Upside: +38.13%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $185.58
Upside: +16.93%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $22.97
Upside: +39.31%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $14.70
Upside: +240.14%
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $30.99
Upside: +45.21%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $30.77
Upside: +72.25%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.75
Upside: +2,985.71%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $6.94
Upside: +116.14%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $9.64
Upside: +273.44%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $32.48
Upside: +115.52%
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $0.70
Upside: +8,471.43%